Developer docs
API playgroundTry for free, no card

Search company profiles

Likarda

Full company profile

uuid0000jd7

Namestring
Likarda
Legal namestring
Likarda, Inc.
Websiteurl
likarda.com
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKansas City, United States
HQ citystring
Kansas City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hydrogel encapsulation platform, cell therapy delivery, biologic drug delivery, cryopreservation logistics, biotech licensing services
Industry1 code
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy & Biologic Drug Delivery Platform
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Feasibility Studies
TypeProfessional Services
Description

Revenue-generating feasibility studies with top-tier biopharma and biotech companies to validate compatibility of CSS® platform with partner therapeutics. Structured as paid engagements with 6-8 week timelines.

likarda.com
2Licensing Revenue
TypeLicensing Royalties
Description

Flexible licensing model including field-of-use or indication-specific licensing (exclusive or non-exclusive) with stage-gated terms: feasibility to development to commercialization. Economics include upfront fees, milestone payments, and possible royalties.

likarda.com
3Equipment Sales
TypeHardware Sales
Description

EncapSure™ CSS® encapsulation instrument sales to CDMOs and partners for in-house use, with recurring revenue potential through services and consumables.

likarda.com
4Co-development Partnerships
TypeManaged Services
Description

Revenue-generating partnerships for co-development of delivery solutions with biopharma companies, expanding growing intellectual property portfolio and de-risking regulatory pathways for partners.

likarda.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details2 tiers
1Custom feasibility study programs for validation of CSS® compatibility
ModelOtherBilling cadenceMulti-year contract
Notes

Feasibility studies are structured engagements with dedicated program leads, customized hydrogel formulations, progress meetings, and final reports. 6-8 week timelines.

likarda.com
2Licensing terms for technology access and commercialization
ModelLicensing/ royaltiesBilling cadenceMulti-year contract
Notes

Field-of-use or indication-specific licensing (exclusive or non-exclusive). Stage-gated terms: feasibility → development → commercialization. Economics: upfront fees + milestone payments + possible royalties. Flexible and negotiable.

likarda.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 9 records shown
1VitaCell™
Description

Injectable hydrogel for timed release of therapeutic cells. A biodegradable hydrogel-based delivery system designed to encapsulate therapeutic cells and release them over a controlled period within the body.

likarda.com
+8 more records
Core offering1 text field

Likarda develops and licenses a proprietary hydrogel-based drug delivery platform called Core-Shell Spherification (CSS), which encapsulates cells, biologics, and small molecules in tunable hydrogel shells to enable sustained release, immune shielding, and improved stability. The company monetizes this platform through paid feasibility studies, stage-gated licensing deals with upfront fees, milestone payments, and royalties, co-development partnerships with biopharma and biotech firms, and direct sales of its EncapSure CSS encapsulation equipment to CDMOs. It also offers productized sub-brands (VitaCell, ViscoCell, EnduraCell, LiberaCell, AegisCell, AegisBio, NovoSphere, Provia) and an AI-powered formulation tool (PPA) that accelerate partner drug delivery programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Liver spheroids maintained >80% viability and function post-thaw using LiberaCell™
+6 more records
Product overview1 text field

Likarda is a hydrogel-based drug delivery technology company offering a modular platform centered on Core-Shell Spherification (CSS), the first fully customizable hydrogel encapsulation technology for cell therapies, biologics, and small molecules. The portfolio spans three solution categories: Cell Therapies (VitaCell for timed cell release, ViscoCell for joint applications, EnduraCell for long-term immune protection); Cryopreservation and Logistics (LiberaCell and AegisCell for cell protection, AegisBio for biologics); and Large and Small Molecule Delivery (NovoSphere for lifecycle extension, Provia for off-the-shelf injectable gel). Supporting technology includes Predictive Polymer Analytics AI platform for formulation optimization and EncapSure equipment for GMP-scale encapsulation.

Product and service13 records
1Core-Shell Spherification (CSS) Platform
CategoryPlatform Technology
Description

Proprietary hydrogel encapsulation platform that surrounds cells, peptides, proteins, antibodies, and scaffolds in injectable hydrogel microbeads for sustained delivery, immune shielding, and controlled release from hours to months. Sold to biopharma, biotech, and CDMOs through feasibility studies, licensing, and co-development.

2VitaCell
CategoryCell Therapy Delivery Product
Description

Biodegradable hydrogel microbead delivery system for controlled cell therapy release, compatible with immune cells, regenerative medicine, and localized treatments including CAR-T cells. Eliminates the need for surgical retrieval and supports precision dosing.

3ViscoCell
CategoryCell Therapy Delivery Product
Description

Injectable stem cell hydrogel optimized for high-motion, load-bearing environments such as joints. Formulated with viscosity and crosslinking properties that mimic synovial fluid to support cartilage regeneration and osteoarthritis treatment.

4EnduraCell
CategoryCell Therapy Delivery Product
Description

Long-term immune-protective cell encapsulation platform providing sustained delivery of therapeutic cells without systemic immunosuppression. Enables durable, immune-shielded treatments for diabetes, liver disease, and other chronic conditions.

5LiberaCell
CategoryCryopreservation Product
Description

Cryopreservation system using hydrogel microbeads to protect sensitive cells during freezing, storage, and shipping without liquid nitrogen. Enables dry ice transport with release-on-demand recovery at the point of use.

6AegisCell
CategoryCryopreservation Product
Description

Ready-to-use, bead-free protective gel matrix for flexible storage and transport of fresh and frozen cell therapies. Preserves cell viability without -80°C or liquid nitrogen and fully dissolves with mild buffer.

7AegisBio
CategoryCryopreservation Product
Description

Non-bead hydrogel that protects large molecule biologics during shipping and storage. Prevents aggregation, shields therapeutics from environmental stress, and preserves potency under challenging transit conditions.

8NovoSphere
CategoryMolecule Delivery Product
Description

Reformulation platform for drug lifecycle extension, enabling pharmaceutical companies to convert existing biologics and small molecules into long-acting therapies. Supports 505(b)(2) filings through customized encapsulation with tunable release profiles spanning hours to months.

9Provia
CategoryMolecule Delivery Product
Description

Off-the-shelf injectable polymer gel for targeted, slow-release delivery of biologics, small molecules, and diagnostic agents. Forms a localized depot for sustained release without requiring a CSS instrument.

10Predictive Polymer Analytics (PPA)
CategoryAI Platform / Software
Description

AI-powered formulation design platform using retrieval-augmented generation on Likarda's proprietary terabyte-scale database of polymer performance and encapsulation chemistries. Recommends optimal polymer backbones and conditions for complex therapies including cells, exosomes, peptides, and large-molecule biologics.

11EncapSure CSS Encapsulation Equipment
CategoryEncapsulation Equipment
Description

Closed-system CSS encapsulation instrument for automated microbead generation, modular fluid control, combined rinse and crosslinking workflows, and integrated QC. GMP-ready for preclinical through commercial use, sold directly to CDMOs and partners for in-house GMP manufacturing.

12CSS Feasibility Study
CategoryProfessional Service
Description

Structured 6-8 week engagement partnering with clients to design and test customized CSS encapsulation solutions tailored to specific therapeutic goals and product needs. Includes dedicated program leads, customized hydrogel formulations, progress meetings, and final reports.

13CSS Preclinical Encapsulation Services
CategoryProfessional Service
Description

Preclinical encapsulation services supporting PK/PD studies, dosing frequency optimization, biodistribution assessment, and immune shielding in rodent and large animal models for biopharma and biotech partners.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Strategic partnership integrating Likarda's CSS® platform with Tiny Cargo's vesicle-based technologies to address key drug delivery challenges including poor stability, rapid clearance, and lack of localization. Focus on advancing delivery of biologics, peptides, and small molecules through combined hydrogel encapsulation and vesicle-mediated transport.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-09
Description

Strategic partnership to accelerate biologic drug development and delivery. Axio BioPharma brings AI biomanufacturing capabilities while Likarda contributes CSS® encapsulation technology for next-generation delivery solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-11
Description

Grant funding to develop advanced cell therapy using CSS® hydrogel encapsulation for antibody-secreting cells targeting infectious diseases (malaria, HIV, tuberculosis) in developing countries. Aims to achieve 6-12 month antibody release improving treatment adherence.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-11
Description

Partnership to develop extended-release injectable hormone therapies using Likarda's CSS® platform technology for improved patient compliance and therapeutic outcomes.

5Cold Chain Technologies
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-03
Description

Exclusive partnership to revolutionize cell therapy material transportation and storage by integrating AegisCell™ into Cold Chain Technologies' logistics solutions. Enables dry ice shipment of cell therapies without sacrificing viability or function, making global distribution simpler and more cost-effective.

likarda.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-10-10
Description

Novel tech cryo partnership focused on cryopreservation solutions combining Evia Bio's technologies with Likarda's LiberaCell™ platform.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-02-17
Description

License option agreement for application of Likarda's technology to eQcell's cell therapy products.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner in regenerative medicine ecosystem, collaborating on manufacturing and commercialization of cell therapy technologies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner, providing funding and research collaboration for diabetes and digestive/kidney disease cell therapy applications.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner for animal health applications using Likarda's cell therapy delivery technologies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner in biotech tools ecosystem supporting innovation in biologics and cell therapy development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO offering mammalian biomanufacturing, cell and gene therapy services, and bioprocessing technologies. Comparable to Likarda in serving biopharma with delivery and manufacturing solutions, particularly in cell therapy.

2Aspect Biosystems
TypeEmerging player
Description

Develops 3D bioprinted tissue therapeutics and microfluidic encapsulation platforms. Comparable to Likarda in applying hydrogel/biomaterial encapsulation to cell-based therapeutics, though focused on tissue printing rather than delivery microbeads.

TypeOthers
Description

Specialty drug delivery company built around long-acting injectable depots and sustained-release formulations. Comparable to Likarda's NovoSphere/Provia product lines that extend dosing intervals of large-molecule biologics.

TypeEmerging player
Description

Contract development organization with cell therapy, biologics, and small molecule capabilities serving biopharma. Comparable as a discovery-to-manufacturing platform partner serving similar biopharma customers as Likarda.

TypeBroad incumbent
Description

Bioprocessing and lab products provider serving biopharma manufacturing, including cell and gene therapy workflows. Comparable as an upstream enabler of biopharma manufacturing that Likarda's CDMO customers depend on.

TypeBroad incumbent
Description

Major CDMO with biologics, cell therapy, and drug product capabilities serving biopharma partners. Comparable as a delivery/encapsulation partner to biopharma and CDMO clients, though at much greater scale and breadth.

TypeBroad incumbent
Description

Life science tools and consumables company supporting cell therapy, biologics, and diagnostics R&D and manufacturing. Comparable as a supplier of enabling tools and reagents consumed by Likarda's biopharma and CDMO customers.

TypeEmerging player
Description

Clinical-stage biotech developing cell-in-capsule therapies for diabetes and cancer using proprietary encapsulation. Directly comparable to Likarda's EnduraCell™ platform in encapsulating insulin-producing cells for diabetes.

9Pluristem Therapeutics
TypeEmerging player
Description

Cell therapy company developing placenta-derived cell therapies with proprietary 3D manufacturing. Comparable as a cell therapy platform player, though focused on the cell product itself rather than the delivery/encapsulation technology.

TypeBroad incumbent
Description

Established drug delivery platform company using its ENHANZE® technology to enable subcutaneous delivery of biologics. Comparable as a platform-based drug delivery licensor to biopharma, but at much larger scale and with commercialized technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Likarda

Cell Therapy & Biologic Drug Delivery Platformlikarda.com

Likarda firmographics

Firmographics
Name
Likarda
Legal name
Likarda, Inc.
Website
https://likarda.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Likarda industry classification

Industry
Product category
Cell Therapy & Biologic Drug Delivery Platform
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)

Keywords

  • Hydrogel encapsulation platform
  • Cell therapy delivery
  • Biologic drug delivery
  • Cryopreservation logistics
  • Biotech licensing services

Where Likarda is headquartered

Location

Headquarters

HQ city
Kansas City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Likarda business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Feasibility Studies: Revenue-generating feasibility studies with top-tier biopharma and biotech companies to validate compatibility of CSS® platform with partner therapeutics. Structured as paid engagements with 6-8 week timelines.
  2. Licensing Revenue: Flexible licensing model including field-of-use or indication-specific licensing (exclusive or non-exclusive) with stage-gated terms: feasibility to development to commercialization. Economics include upfront fees, milestone payments, and possible royalties.
  3. Equipment Sales: EncapSure™ CSS® encapsulation instrument sales to CDMOs and partners for in-house use, with recurring revenue potential through services and consumables.
  4. Co-development Partnerships: Revenue-generating partnerships for co-development of delivery solutions with biopharma companies, expanding growing intellectual property portfolio and de-risking regulatory pathways for partners.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom feasibility study programs for validation of CSS® compatibility
Licensing/ royaltiesMulti-year contractLicensing terms for technology access and commercialization

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Likarda product offering

Product offering

Core offering

Likarda develops and licenses a proprietary hydrogel-based drug delivery platform called Core-Shell Spherification (CSS), which encapsulates cells, biologics, and small molecules in tunable hydrogel shells to enable sustained release, immune shielding, and improved stability. The company monetizes this platform through paid feasibility studies, stage-gated licensing deals with upfront fees, milestone payments, and royalties, co-development partnerships with biopharma and biotech firms, and direct sales of its EncapSure CSS encapsulation equipment to CDMOs. It also offers productized sub-brands (VitaCell, ViscoCell, EnduraCell, LiberaCell, AegisCell, AegisBio, NovoSphere, Provia) and an AI-powered formulation tool (PPA) that accelerate partner drug delivery programs.

Product overview

Likarda is a hydrogel-based drug delivery technology company offering a modular platform centered on Core-Shell Spherification (CSS), the first fully customizable hydrogel encapsulation technology for cell therapies, biologics, and small molecules. The portfolio spans three solution categories: Cell Therapies (VitaCell for timed cell release, ViscoCell for joint applications, EnduraCell for long-term immune protection); Cryopreservation and Logistics (LiberaCell and AegisCell for cell protection, AegisBio for biologics); and Large and Small Molecule Delivery (NovoSphere for lifecycle extension, Provia for off-the-shelf injectable gel). Supporting technology includes Predictive Polymer Analytics AI platform for formulation optimization and EncapSure equipment for GMP-scale encapsulation.

Differentiator

Problem solved

Functional benefit

Brands

  • VitaCell™: Injectable hydrogel for timed release of therapeutic cells. A biodegradable hydrogel-based delivery system designed to encapsulate therapeutic cells and release them over a controlled period within the body.
  • ViscoCell™
  • EnduraCell™
  • LiberaCell™
  • AegisCell™
  • AegisBio™
  • NovoSphere™
  • Provia™
  • Predictive Polymer Analytics™ (PPA™)

Products and services

  • Core-Shell Spherification (CSS) Platform Proprietary hydrogel encapsulation platform that surrounds cells, peptides, proteins, antibodies, and scaffolds in injectable hydrogel microbeads for sustained delivery, immune shielding, and controlled release from hours to months. Sold to biopharma, biotech, and CDMOs through feasibility studies, licensing, and co-development.
  • VitaCell Biodegradable hydrogel microbead delivery system for controlled cell therapy release, compatible with immune cells, regenerative medicine, and localized treatments including CAR-T cells. Eliminates the need for surgical retrieval and supports precision dosing.
  • ViscoCell Injectable stem cell hydrogel optimized for high-motion, load-bearing environments such as joints. Formulated with viscosity and crosslinking properties that mimic synovial fluid to support cartilage regeneration and osteoarthritis treatment.
  • EnduraCell Long-term immune-protective cell encapsulation platform providing sustained delivery of therapeutic cells without systemic immunosuppression. Enables durable, immune-shielded treatments for diabetes, liver disease, and other chronic conditions.
  • LiberaCell Cryopreservation system using hydrogel microbeads to protect sensitive cells during freezing, storage, and shipping without liquid nitrogen. Enables dry ice transport with release-on-demand recovery at the point of use.
  • AegisCell Ready-to-use, bead-free protective gel matrix for flexible storage and transport of fresh and frozen cell therapies. Preserves cell viability without -80°C or liquid nitrogen and fully dissolves with mild buffer.
  • AegisBio Non-bead hydrogel that protects large molecule biologics during shipping and storage. Prevents aggregation, shields therapeutics from environmental stress, and preserves potency under challenging transit conditions.
  • NovoSphere Reformulation platform for drug lifecycle extension, enabling pharmaceutical companies to convert existing biologics and small molecules into long-acting therapies. Supports 505(b)(2) filings through customized encapsulation with tunable release profiles spanning hours to months.
  • Provia Off-the-shelf injectable polymer gel for targeted, slow-release delivery of biologics, small molecules, and diagnostic agents. Forms a localized depot for sustained release without requiring a CSS instrument.
  • Predictive Polymer Analytics (PPA) AI-powered formulation design platform using retrieval-augmented generation on Likarda's proprietary terabyte-scale database of polymer performance and encapsulation chemistries. Recommends optimal polymer backbones and conditions for complex therapies including cells, exosomes, peptides, and large-molecule biologics.
  • EncapSure CSS Encapsulation Equipment Closed-system CSS encapsulation instrument for automated microbead generation, modular fluid control, combined rinse and crosslinking workflows, and integrated QC. GMP-ready for preclinical through commercial use, sold directly to CDMOs and partners for in-house GMP manufacturing.
  • CSS Feasibility Study Structured 6-8 week engagement partnering with clients to design and test customized CSS encapsulation solutions tailored to specific therapeutic goals and product needs. Includes dedicated program leads, customized hydrogel formulations, progress meetings, and final reports.
  • CSS Preclinical Encapsulation Services Preclinical encapsulation services supporting PK/PD studies, dosing frequency optimization, biodistribution assessment, and immune shielding in rodent and large animal models for biopharma and biotech partners.

Quantifiable outcome

  • Liver spheroids maintained >80% viability and function post-thaw using LiberaCell™
  • +6 more outcomes

Companies that use Likarda

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Likarda technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Likarda partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • The Tiny Cargo CompanycoreStrategic or Co-development Partner · 7 April 2026Strategic partnership integrating Likarda's CSS® platform with Tiny Cargo's vesicle-based technologies to address key drug delivery challenges including poor stability, rapid clearance, and lack of localization. Focus on advancing delivery of biologics, peptides, and small molecules through combined hydrogel encapsulation and vesicle-mediated transport.
  • Axio BioPharmacoreStrategic or Co-development Partner · 9 June 2025Strategic partnership to accelerate biologic drug development and delivery. Axio BioPharma brings AI biomanufacturing capabilities while Likarda contributes CSS® encapsulation technology for next-generation delivery solutions.
  • Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 11 March 2025Grant funding to develop advanced cell therapy using CSS® hydrogel encapsulation for antibody-secreting cells targeting infectious diseases (malaria, HIV, tuberculosis) in developing countries. Aims to achieve 6-12 month antibody release improving treatment adherence.
  • VitalTE Life SciencescoreStrategic or Co-development Partner · 11 December 2024Partnership to develop extended-release injectable hormone therapies using Likarda's CSS® platform technology for improved patient compliance and therapeutic outcomes.
  • Cold Chain TechnologiescoreStrategic or Co-development Partner · 3 June 2024Exclusive partnership to revolutionize cell therapy material transportation and storage by integrating AegisCell™ into Cold Chain Technologies' logistics solutions. Enables dry ice shipment of cell therapies without sacrificing viability or function, making global distribution simpler and more cost-effective.
  • Evia BiominorStrategic or Co-development Partner · 10 October 2023Novel tech cryo partnership focused on cryopreservation solutions combining Evia Bio's technologies with Likarda's LiberaCell™ platform.
  • eQcellminorOEM/ Whitelabel/ Licensing Partner · 17 February 2022License option agreement for application of Likarda's technology to eQcell's cell therapy products.
  • ARMI (Advanced Regenerative Manufacturing Institute)minorStrategic or Co-development PartnerListed as strategic partner in regenerative medicine ecosystem, collaborating on manufacturing and commercialization of cell therapy technologies.
  • NIH - National Institute of Diabetes and Digestive and Kidney DiseasesminorStrategic or Co-development PartnerListed as strategic partner, providing funding and research collaboration for diabetes and digestive/kidney disease cell therapy applications.
  • EDGE Animal HealthminorStrategic or Co-development PartnerListed as strategic partner for animal health applications using Likarda's cell therapy delivery technologies.
  • BioTools InnovatorminorStrategic or Co-development PartnerListed as strategic partner in biotech tools ecosystem supporting innovation in biologics and cell therapy development.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Likarda competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Global CDMO offering mammalian biomanufacturing, cell and gene therapy services, and bioprocessing technologies. Comparable to Likarda in serving biopharma with delivery and manufacturing solutions, particularly in cell therapy.
  • Sartorius: Bioprocessing and lab products provider serving biopharma manufacturing, including cell and gene therapy workflows. Comparable as an upstream enabler of biopharma manufacturing that Likarda's CDMO customers depend on.
  • Catalent: Major CDMO with biologics, cell therapy, and drug product capabilities serving biopharma partners. Comparable as a delivery/encapsulation partner to biopharma and CDMO clients, though at much greater scale and breadth.
  • Bio-Techne: Life science tools and consumables company supporting cell therapy, biologics, and diagnostics R&D and manufacturing. Comparable as a supplier of enabling tools and reagents consumed by Likarda's biopharma and CDMO customers.
  • Halozyme Therapeutics: Established drug delivery platform company using its ENHANZE® technology to enable subcutaneous delivery of biologics. Comparable as a platform-based drug delivery licensor to biopharma, but at much larger scale and with commercialized technology.

Emerging players

  • Aspect Biosystems: Develops 3D bioprinted tissue therapeutics and microfluidic encapsulation platforms. Comparable to Likarda in applying hydrogel/biomaterial encapsulation to cell-based therapeutics, though focused on tissue printing rather than delivery microbeads.
  • Evotec: Contract development organization with cell therapy, biologics, and small molecule capabilities serving biopharma. Comparable as a discovery-to-manufacturing platform partner serving similar biopharma customers as Likarda.
  • PharmaCyte Biotech: Clinical-stage biotech developing cell-in-capsule therapies for diabetes and cancer using proprietary encapsulation. Directly comparable to Likarda's EnduraCell™ platform in encapsulating insulin-producing cells for diabetes.
  • Pluristem Therapeutics: Cell therapy company developing placenta-derived cell therapies with proprietary 3D manufacturing. Comparable as a cell therapy platform player, though focused on the cell product itself rather than the delivery/encapsulation technology.

Others

  • Pacira BioSciences: Specialty drug delivery company built around long-acting injectable depots and sustained-release formulations. Comparable to Likarda's NovoSphere/Provia product lines that extend dosing intervals of large-molecule biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Likarda social profiles

Digital presence

Likarda financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Likarda leadership team

Management profile

Number of profiles

Profiles7 records

Likarda funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Likarda M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Likarda

What does Likarda do?

Likarda develops and licenses a proprietary hydrogel-based drug delivery platform called Core-Shell Spherification (CSS), which encapsulates cells, biologics, and small molecules in tunable hydrogel shells to enable sustained release, immune shielding, and improved stability. The company monetizes this platform through paid feasibility studies, stage-gated licensing deals with upfront fees, milestone payments, and royalties, co-development partnerships with biopharma and biotech firms, and direct sales of its EncapSure CSS encapsulation equipment to CDMOs. It also offers productized sub-brands (VitaCell, ViscoCell, EnduraCell, LiberaCell, AegisCell, AegisBio, NovoSphere, Provia) and an AI-powered formulation tool (PPA) that accelerate partner drug delivery programs.

Is Likarda a public or private company?

Likarda is a private company. It is classified as venture growth investor backed and is currently operating.

When was Likarda founded?

Likarda was founded in 2012. It employs 11 to 50 people.

Where is Likarda based?

Likarda is headquartered in Kansas City, United States, in the North America region.

How does Likarda make money?

Four revenue lines are on record. Feasibility Studies are the primary driver. The others are licensing Revenue, equipment Sales and co-development Partnerships.

Who are Likarda's main competitors?

Broad incumbents on record are Lonza, Sartorius, Catalent, Bio-Techne and Halozyme Therapeutics. Emerging players are Aspect Biosystems, Evotec, PharmaCyte Biotech and Pluristem Therapeutics. Pacira BioSciences is listed as an others.

Does Likarda have an API?

No public API is recorded for Likarda.

What industry is Likarda in?

Likarda's product category is Cell Therapy & Biologic Drug Delivery Platform. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceMiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell TherapyMiNK Therapeutics' clinical-stage agenT-797 iNKT platform was selected for an ARPA-H BioStabilization Systems program to develop room-temperature cell therapy storage. ARPA-H has committed up to $87 million across the four-year initiative. The collaboration aims to reduce cold-chain dependence and expand access to allogeneic cell therapies.PrwebLikarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small MoleculesLikarda, Inc., a hydrogel-based drug delivery technology company, announced a strategic partnership with Tiny Cargo, an extracellular vesicle delivery systems innovator, to advance the delivery of biologics, peptides, and small molecules. The collaboration will integrate Likarda's Core-Shell Spherification platform with Tiny Cargo's vesicle-based technologies to address key drug delivery challenges including poor stability, rapid clearance, and lack of localization.BioXconomyCrisis as catalyst: From Chernobyl evacuation to biotech innovationVnook, CEO of Likarda, discusses her journey from a Chernobyl refugee to a biotech entrepreneur, highlighting her leadership philosophy and career trajectory in the life sciences sector. She outlines key challenges facing biotech startups, including capital constraints and regulatory hurdles, while emphasizing the importance of agility and strategic resource allocation. The article also details her involvement with various ventures such as Oral BioLife Inc., Kaida Biopharma, and Brainstorm Diagnostics.PR NewswireAxio BioPharma and Likarda Announce Strategic Partnership to Accelerate Biologic Drug Development and DeliveryAxio BioPharma and Likarda Inc. announced a strategic partnership to integrate AI-powered protein manufacturing with advanced drug delivery technologies for biologic drug development. The collaboration involves Axio incorporating Likarda's Core-Shell Spherification technology into its services, while Likarda will offer Axio's discovery-to-GMP manufacturing capabilities to its clients. This move aims to streamline workflows and accelerate clinical manufacturing timelines for monoclonal antibodies and other biologics.LikardaLikarda Receives Grant to Deliver Antibody-Secreting Cell Therapy with CSS® Hydrogel EncapsulationLikarda received a Gates Foundation grant to develop a CSS hydrogel formulation that protects antibody-secreting cells for up to 12 months. The goal is to enable sustained antibody release for infectious diseases like malaria, HIV, and tuberculosis, with an in vivo rodent study planned.PharmiWeb.comLikarda Receives Grant to Deliver Antibody-Secreting Cell Therapy with CSS® Hydrogel EncapsulationLikarda received a Gates Foundation grant to develop a hydrogel formulation that protects antibody-secreting cells for up to 12 months. The company aims to test an optimized formulation in an in vivo rodent study. The grant supports its CSS platform for long-term therapeutic delivery.biopharma-reporter.comHow Stella Vnook is 'infusing innovation' into cell therapies with Likarda's technologyStella Vnook, CEO of Likarda, leads a team developing core-shell spherification technology that coats cell therapies in hydrogel to improve tumor targeting and cell viability. The platform also enables dry-ice transport, reducing cell loss, and is expanding into large-molecule biologics for sustained release.American City Business JournalsKansas City startup Likarda makes business plans for 2024Kansas City biotech startup Likarda plans to launch products and spin out its animal health division in 2024. It expects revenue to grow three to four times and become profitable, raising $15 million in a Series A round. The company is working with pharma partners and planning clinical trials for an osteoarthritis treatment.BioSpaceLikarda Announces Core Shell Spherification for Large Molecule Biologics and Welcomes New CEO, Dr. Stella VnookLikarda LLC announced the expansion of its Core Shell Spherification (CSS) platform technology to include large molecule biologics, such as antibodies and peptides, alongside the appointment of Dr. Stella Vnook as its new CEO. The company highlighted a collaboration with an antibody partner to develop an extended-release formulation that maintains therapeutic levels for two months via a single injection. These developments aim to address industry challenges regarding targeted delivery, dosing stability, and intellectual property protection.FinSMEsLikarda Raises $4M in Series A FundingLikarda, a Kansas City biotech lab, raised $4M in Series A funding from Werth Family Investment Associates. The company develops a proprietary diabetes treatment for dogs and cats using insulin-producing cell clusters. It plans to scale from hundreds to thousands of animals, with clinical research launching by end of 2017.